-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
-
Summary
-
Teva Pharmaceutical Industries Ltd quarterly/annual Amortization of Intangible Assets history and growth rate from Q2 2017 to Q3 2024.
- Teva Pharmaceutical Industries Ltd Amortization of Intangible Assets for the quarter ending September 30, 2024 was $146M, a 0.69% increase year-over-year.
- Teva Pharmaceutical Industries Ltd Amortization of Intangible Assets for the twelve months ending September 30, 2024 was $588M, a 6.22% decline year-over-year.
- Teva Pharmaceutical Industries Ltd annual Amortization of Intangible Assets for 2023 was $616M, a 15.8% decline from 2022.
- Teva Pharmaceutical Industries Ltd annual Amortization of Intangible Assets for 2022 was $732M, a 8.73% decline from 2021.
- Teva Pharmaceutical Industries Ltd annual Amortization of Intangible Assets for 2021 was $802M, a 21.4% decline from 2020.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)